Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1;34(6):344-350.
doi: 10.1097/GCO.0000000000000819. Epub 2022 Aug 19.

Progestins of today and tomorrow

Serena Liu  1 , Olga Kciuk  2 , Madelyn Frank  3 , Nichole Tyson  4
Affiliations
Review

Progestins of today and tomorrow

Serena Liu et al. Curr Opin Obstet Gynecol. .

Abstract

Purpose of review: To review the current literature on the multiple types and uses of progestins in reproductive healthcare.

Recent findings: Progestins for contraceptive use are available in multiple forms, with the ongoing development of transdermal, intravaginal, and male contraception formulations. Noncontraceptive use of progestins often overlaps with contraceptive indications, which allows for simultaneous multipurpose progestin use, especially in reproductive-aged patients. More studies are needed to determine contraceptive doses of progestins used for noncontraceptive purposes. Side effect profiles of progestins are dependent on their formulation and cross-reactivity with other steroid receptors. Development of newer progestins includes manipulating pharmacologic properties to avoid undesired side effects.

Summary: Progestins have multiple uses in reproductive healthcare, including contraception, menstrual suppression, endometrial protection, and hormonal replacement therapy. The development of progestins for these indications can expand therapy for people with contraindications to estrogen-based hormonal therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Royer PA, Jones KP. Progestins for contraception: modern delivery systems and novel formulations. Clin Obstet Gynecol 2014; 57:644–658.
    1. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003; 46:7–16.
    1. Creinin MD, Jensen JT. Oral contraceptive generations – time to stop using a marketing myth to define nomenclature. Contraception 2020; 102:143–144.
    1. Słopień R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Prz Menopauzalny 2018; 17:1–4.
    1. Zimmerman Y, Eijkemans MJC, Coelingh Bennink HJT, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:76–105.